DE60015594D1 - Imidazolderivate und deren verwendung als raf kinase inhibitoren - Google Patents

Imidazolderivate und deren verwendung als raf kinase inhibitoren

Info

Publication number
DE60015594D1
DE60015594D1 DE60015594T DE60015594T DE60015594D1 DE 60015594 D1 DE60015594 D1 DE 60015594D1 DE 60015594 T DE60015594 T DE 60015594T DE 60015594 T DE60015594 T DE 60015594T DE 60015594 D1 DE60015594 D1 DE 60015594D1
Authority
DE
Germany
Prior art keywords
kinase inhibitors
imidazole derivatives
raf kinase
occurred
excessive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60015594T
Other languages
English (en)
Other versions
DE60015594T2 (de
Inventor
David Dean
Peter Lovell
Andrew Takle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60015594D1 publication Critical patent/DE60015594D1/de
Publication of DE60015594T2 publication Critical patent/DE60015594T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
DE60015594T 1999-11-22 2000-11-20 Imidazolderivate und deren verwendung als raf kinase inhibitoren Expired - Fee Related DE60015594T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US16688599P 1999-11-22 1999-11-22
US16689599P 1999-11-22 1999-11-22
US16681499P 1999-11-22 1999-11-22
US16688699P 1999-11-22 1999-11-22
US166886P 1999-11-22
US166814P 1999-11-22
US166885P 1999-11-22
US166895P 1999-11-22
PCT/GB2000/004413 WO2001038324A2 (en) 1999-11-22 2000-11-20 Imidazole derivatives and their use as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60015594D1 true DE60015594D1 (de) 2004-12-09
DE60015594T2 DE60015594T2 (de) 2005-10-27

Family

ID=27496721

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60015594T Expired - Fee Related DE60015594T2 (de) 1999-11-22 2000-11-20 Imidazolderivate und deren verwendung als raf kinase inhibitoren
DE60037597T Expired - Fee Related DE60037597T2 (de) 1999-11-22 2000-11-20 Imidazol- Derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60037597T Expired - Fee Related DE60037597T2 (de) 1999-11-22 2000-11-20 Imidazol- Derivate

Country Status (21)

Country Link
US (3) US7189745B1 (de)
EP (2) EP1232153B1 (de)
JP (2) JP2003514906A (de)
KR (1) KR20020050294A (de)
CN (1) CN1543346A (de)
AT (2) ATE382044T1 (de)
AU (2) AU1623601A (de)
BR (1) BR0015532A (de)
CA (1) CA2395564A1 (de)
CZ (1) CZ20021746A3 (de)
DE (2) DE60015594T2 (de)
ES (2) ES2228629T3 (de)
HK (1) HK1050190A1 (de)
HU (1) HUP0203403A3 (de)
IL (2) IL149150A0 (de)
MX (1) MXPA02005106A (de)
NO (1) NO20022318D0 (de)
NZ (1) NZ518032A (de)
PL (1) PL355912A1 (de)
TR (1) TR200201364T2 (de)
WO (2) WO2001037835A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
MXPA02005106A (es) 1999-11-22 2002-11-07 Smithkline Beecham Plc Compuestos novedosos.
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
JP4217480B2 (ja) * 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1423383B1 (de) 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf-kinase inhibitoren
EP1432699A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
EP1537112B1 (de) 2002-08-06 2006-04-19 Astrazeneca AB Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
EP1539121A4 (de) 2002-08-29 2008-08-13 Scios Inc Verfahren zur forderung der osteogenese
EP2426122A1 (de) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylenharnstoffderivate als Inhibitoren von RAF Kinase
BR0315580A (pt) * 2002-10-24 2005-08-30 Merck Patent Gmbh Derivados de metileno uréia
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
US7361669B2 (en) 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
BRPI0414869A (pt) * 2003-10-02 2006-11-28 Irm Llc compostos e composições como inibidores da proteìna quinase
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2005082853A1 (en) * 2004-02-26 2005-09-09 Merck Patent Gmbh Semicarbazide derivatives as kinase inhibitors
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
WO2007016286A1 (en) * 2005-07-28 2007-02-08 Janssen Pharmaceutica N.V. Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine
EP1934213A1 (de) 2005-09-30 2008-06-25 Astra Zeneca AB Imidazo [1,2-a] pyridin mit antizellproliferationswirkung
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
CA2689092C (en) 2007-06-07 2013-01-15 Amgen Inc. Raf kinase modulators and methods of use
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8129394B2 (en) * 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8835450B2 (en) * 2009-10-08 2014-09-16 Glaxosmithkline Llc Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
PL2488033T3 (pl) * 2009-10-16 2019-12-31 Novartis Ag Kombinacja zawierająca inhibitor MEK i inhibitor B-raf
WO2011077387A1 (en) * 2009-12-22 2011-06-30 Csir Inhibition of the activity of kinase and synthetase enzymes
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10605785B2 (en) * 2017-06-07 2020-03-31 General Electric Company Sensor system and method

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4447413A (en) * 1980-05-08 1984-05-08 Aviation Chemical, Inc. Drift influencing composition
US4348404A (en) 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
DD201677A5 (de) 1980-07-25 1983-08-03 Ciba Geigy Verfahren zur herstellung von trisubstituierten imidazolderivaten
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5179117A (en) 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
DE69401486T2 (de) 1993-11-12 1997-04-30 Ishihara Sangyo Kaisha Verfahren zur Herstellung 2-cyanoimidazol Derivate
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
EP0833664A1 (de) 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0889887A4 (de) 1996-03-25 2003-06-11 Smithkline Beecham Corp Behandlung von verletzungen des zentralen nervensystems
WO1997036587A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. A method of treating cancer
JP3418624B2 (ja) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
UA67732C2 (uk) 1996-10-15 2004-07-15 Г.Д. Сьорл & Ко. Інгібітори циклооксигенази-2 для лікування і попередження неоплазії та спосіб лікування
JP4380803B2 (ja) 1997-06-12 2009-12-09 アベンテイス・フアルマ・リミテツド イミダゾリル−環式アセタール
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
KR20010014288A (ko) 1997-06-30 2001-02-26 오르토-맥네일 파마슈티칼, 인코퍼레이티드 염증성 질환의 치료에 유용한 2-치환된 이미다졸
WO1999021555A2 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
UA67763C2 (uk) * 1997-12-22 2004-07-15 Байер Фармасьютікалс Корпорейшн Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf
EP1049664B1 (de) 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
KR20010025087A (ko) 1998-05-22 2001-03-26 스튜어트 알. 수터 신규한 2-알킬 치환된 이미다졸 화합물
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
AU2039800A (en) 1998-12-04 2000-06-26 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
WO2000064422A2 (en) 1999-04-27 2000-11-02 Smithkline Beecham P.L.C. Novel treatment of neurotraumatic conditions with raf inhibitor
MXPA02005106A (es) 1999-11-22 2002-11-07 Smithkline Beecham Plc Compuestos novedosos.
WO2001066539A1 (en) 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
EP1318992B1 (de) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazolderivate als raf-kinase-inhibitoren
JP4217480B2 (ja) 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432699A1 (de) 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
EP1423383B1 (de) 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf-kinase inhibitoren
EP1432703A1 (de) 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
DE60015594T2 (de) 2005-10-27
EP1233769A1 (de) 2002-08-28
HUP0203403A2 (hu) 2003-02-28
ATE382044T1 (de) 2008-01-15
WO2001038324A2 (en) 2001-05-31
JP2003514906A (ja) 2003-04-22
NO20022318L (no) 2002-05-15
KR20020050294A (ko) 2002-06-26
JP2003514860A (ja) 2003-04-22
PL355912A1 (en) 2004-05-31
DE60037597T2 (de) 2008-12-11
EP1232153B1 (de) 2004-11-03
WO2001037835A1 (en) 2001-05-31
ATE281451T1 (de) 2004-11-15
AU1623601A (en) 2001-06-04
US7026336B1 (en) 2006-04-11
WO2001038324A3 (en) 2002-05-10
EP1233769A4 (de) 2004-12-29
IL149150A0 (en) 2002-12-01
TR200201364T2 (tr) 2002-10-21
CZ20021746A3 (cs) 2002-10-16
NZ518032A (en) 2004-02-27
US7189745B1 (en) 2007-03-13
NO20022318D0 (no) 2002-05-15
MXPA02005106A (es) 2002-11-07
US20070010534A1 (en) 2007-01-11
CN1543346A (zh) 2004-11-03
BR0015532A (pt) 2002-06-25
CA2395564A1 (en) 2001-05-31
EP1232153A2 (de) 2002-08-21
ES2298165T3 (es) 2008-05-16
HK1050190A1 (zh) 2003-06-13
IL149150A (en) 2007-02-11
ES2228629T3 (es) 2005-04-16
DE60037597D1 (de) 2008-02-07
EP1233769B1 (de) 2007-12-26
HUP0203403A3 (en) 2004-01-28
AU1529901A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
DE60015594D1 (de) Imidazolderivate und deren verwendung als raf kinase inhibitoren
HRP20050059B1 (hr) Novi inhibitori kinaza
DE60005485D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
NO20052733L (no) C-6 modifiserte indazolylpyrrolotriaziner
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
HK1054039A1 (en) Substituded beta-carbolines
ATE301651T1 (de) Substituierte benzimidazole
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
BG105625A (en) Quinoline and quinoxaline compounds as pfgf-receptor and/or lck tyrosine kinase inhibitors
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
DE60129934D1 (de) Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
NO963706L (no) Benzenkondenserte heterosykliske derivater og deres anvendelse
ATE365730T1 (de) Neuartige verbindungen
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
ATE277010T1 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
EP1372648A4 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE50003307D1 (de) Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren
DE50001742D1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee